Competition

Competition - Molina vs. Five Public Rivals

Molina sells the same product to the same customer (a state Medicaid agency or CMS) on roughly the same regulatory terms as five much larger publicly traded peers. The investment question isn't whether Molina has a brand or a network — Humana itself says of this arena that "barriers to entry in our markets are not substantial" [1] — it's whether disciplined operating cost and Medicaid-specific underwriting expertise are enough of an edge to keep earning above-industry medical margin in a bid market where four of the country's largest health insurers can outbid Molina on scale, brand, and balance sheet.

1. The Competitive Bottom Line

Molina's competitive position is operational, not structural — and the franchise quality is real, but it is the kind of advantage that has to be re-earned every year, contract by contract.

The advantage is lower medical cost than the industry on the Medicaid book it serves: Molina's stat filings show it running 200-250 basis points better than the broader Medicaid industry that is itself 300-400 basis points underfunded by current state rates [2]. Molina's own 10-K reinforces the historical pattern: "most of our health plans over the last several years have generally operated with profit margins higher than those of our direct competitors" [3].
It is paired with lower operating cost: Molina's full-year FY2025 G&A ratio was 6.6% (down from 6.7% in FY2024) on a 91.7% consolidated MCR [4], built on operating leverage from a pure-play government book that does not subsidize a commercial sales force [5].
It is not a brand, network, or vertical-integration advantage. Molina is the smallest of the five named public peers by a wide margin and outsources its IT infrastructure, end-user services, data centers, public cloud and application management to a third party under an arrangement extended through 2029 [6].

The single most important rival is Centene Corporation (CNC). Centene is the only other publicly traded peer that runs the same pure-play, government-sponsored, Medicaid-first model, and Molina's FY2025 10-K names it both as a primary Medicaid managed care competitor and as the primary competitor for low-income Marketplace membership [6] [7]. Centene self-describes as the "nation's largest managed care company focused on underserved populations" serving 27.6 million members [8] and the largest Medicaid health insurer with 12.5 million Medicaid members in 30 states [9] — a direct, line-for-line substitute on every state procurement Molina enters and one whose own FY2025 earnings collapsed at the same time Molina's did, confirming the cycle is shared and not idiosyncratic.

The most dangerous competitor type over the next 24 months is the scaled multi-product MCO — UnitedHealth Group, Elevance Health, CVS Health/Aetna — that is, by Molina's own description, showing "renewed interest from large national health plans" in the Medicaid bid market [6]. They cannot underwrite Medicaid any better than Molina can; they can, however, cross-subsidize aggressive bids from commercial profit pools, vertical integration (Optum, Caremark, Carelon), or balance sheets ten-to-thirty times Molina's size.

The peer set comparison is real but asymmetric. Centene is the only true peer; the other four are scale comparators whose Medicaid books are a single line of business inside a much larger company. Read every multiple, margin, and growth rate side-by-side with that asymmetry in mind.

2. The Peer Set - Why These Five

Molina's FY2025 10-K names its primary competitors directly. In Medicaid managed care: "Centene Corporation, CVS Health Corporation, Elevance Health, Inc., UnitedHealth Group Inc., and large not-for-profit healthcare organizations" [6]. In Medicare: "CVS Health Corporation, Humana, Inc., and UnitedHealth Group Inc." [7]. In low-income Marketplace: "Centene Corporation" [7]. The same five-competitor framing appears in the FY2024 10-K [10], so the peer set is stable across consecutive 10-K disclosures and not a one-year artifact.

The peer set has shifted only superficially over five years: the FY2021 10-K listed "Centene, UnitedHealth Group, Anthem, Aetna, and other large not-for-profit healthcare organizations" [11]. Anthem became Elevance Health; Aetna became part of CVS Health. The rivals didn't change — their corporate parents renamed themselves. The competitive arena is structurally the same as it was five years ago.

One indexed peer was rejected from the comparison set: The Cigna Group (CI) is in the corpus but, after Cigna's March 19, 2025 sale of its Medicare Advantage, Medicare PDP, and CareAllies businesses to Health Care Service Corporation, it has no Medicaid managed-care book and no remaining Medicare Advantage book, and it does not appear in Molina's FY2025 10-K Medicaid or Medicare competition lists; Cigna only shows up in Molina's stock-performance peer-group index alongside non-managed-care names like Aflac, MetLife and Prudential [12]. Cigna is not a Molina competitor today; we exclude it.

Molina's 10-K also flags "large not-for-profit healthcare organizations" as Medicaid competitors [6]. These (Blue Cross plans, regional non-profits) are not publicly traded and therefore invisible to any peer screen — readers should treat them as a meaningful share of the Medicaid bid market that no public-company comparison can capture.

Each peer, verified from its own filing

No Results

The cited self-descriptions behind that table: Centene serves "more than 1 in 15 individuals across the nation" with Medicaid (57%), Commercial/Marketplace (21%) and Medicare (19%) revenue mix [8], and is "the largest Medicaid health insurer in the country, serving 12.5 million Medicaid members in 30 states as of December 31, 2025" [9]. UnitedHealth runs Optum + UnitedHealthcare, with a Community & State business serving the "medically underserved" [13] and 8.4 million Medicare Advantage members through CMS contracts [14]. Elevance serves "approximately 45.2 million medical members" across Individual, Employer Group, Medicaid and Medicare [15]. CVS Health serves "more than 37 million people" through health insurance products and a PBM with 87 million plan members [16], with Aetna offering Medicaid/CHIP managed care "on an Insured or ASC basis in 15 states in 2025" [17]. Humana provided coverage to "approximately 5.2 million individual Medicare Advantage members, including approximately 1.0 million members in Florida" [18], with individual MA at 70.3% and state-based Medicaid at 11.2% of revenue [19].

3. Scale and Economics - Where MOH Sits

No Results

Molina sits at the bottom of every scale metric on the table. Revenue of $45.4 billion in FY2025 is one-tenth UnitedHealth's $447 billion and roughly one-quarter Centene's $174 billion [4]. FY2025 was a cycle bottom for the whole arena: Centene swung to a $6.7 billion net loss as Medicaid trend overran state rates and Marketplace risk-adjustment turned adverse — the same pressures that drove Molina's consolidated MCR from 89.1% to 91.7% [4]. UnitedHealth, Elevance, CVS, and Humana retained positive earnings because diversified commercial, Optum/Caremark/Carelon services, and lower Medicaid exposure dampened the same shock that hit the two pure-plays. That is exactly the structural asymmetry the comparison reveals.

Caveats on missing values: CVS Health does not separately disclose long-term debt in the structured corpus data, so enterprise value cannot be reliably computed; CVS operating margin is also not separately reported in the structured ratios file. UnitedHealth's ROE and debt-to-equity are not in the structured ratios file. Member counts at UNH, CVS, and HUM (across all lines combined) are not disclosed as a single comparable aggregate and are intentionally left blank in the table rather than mixing definitions; the column captures Medicaid-relevant figures only where each peer's filing states one directly.

Bubble view: profitability vs. scale

The bubble chart makes the two-axis story visible: Molina is far to the left on revenue (smallest) and roughly middle of the pack on operating margin in a year when the only directly comparable peer (Centene) printed a deeply negative number. The implied comparison is not "Molina vs. peers in normal times" — it is "Molina vs. peers in the same cycle bottom."

4. Where Molina Beats Each Peer

Four advantages, each grounded in the primary record:

4.1 Medicaid underwriting accuracy. The clearest cited evidence is from Q3 FY2025 — the CFO stated on the earnings call that "the industry is 300 to 400 basis points underfunded right now" against medical cost trend, and that the same stat filings show "Molina is still performing 200 to 250 basis points better than the industry. So we need half of what the broader industry needs to get to our target margins" [2]. Molina's own 10-K reinforces the historical pattern: "most of our health plans over the last several years have generally operated with profit margins higher than those of our direct competitors" [3]. This is the most important moat element — it is the actuarial expertise of having underwritten government-program populations since 1980 and not being distracted by a commercial book.

4.2 G&A discipline and operating leverage on a pure-play book. Molina's FY2025 G&A ratio was 6.6%, down from 6.7% in FY2024, on $45.4 billion of revenue [4], with management explicitly attributing the decline to "operating discipline, the continued benefit of operating leverage as we grow our business" [5]. Centralized services across health plans, no commercial sales force, no Optum-like services arm to support, and an IT infrastructure outsourced under a long-term contract [6] — these are the structural elements behind the ratio.

4.3 Bid-market win rate and RFP execution. FY2025 RFP successes and acquisitions represent "nearly \$9 billion of incremental annual premium revenue" [20], including new contracts in Idaho (Medicaid and Medicare), Michigan, Massachusetts, Ohio (Medicare), Wisconsin (Family Care and Family Care Partnership), and the sole-plan Florida Kids award expected to serve approximately 120,000 enrollees [21]. Management quantified the rolling track record on the Q4 FY2025 call: "Our win rate is 80%. \$20 billion of run rate revenue over the past number of years, including the Florida Kids contract…" [22]. The Wisconsin renewal complemented previously announced Georgia and Texas STAR wins to represent "over \$9 billion of Medicaid premium" in the recent cohort [23].

4.4 Marketplace selection discipline (the FY2026 cycle). Molina sized its Marketplace book down deliberately heading into 2026 — "our decision to reduce our exposure in this highly volatile segment" — and stayed concentrated in the silver tier with renewals dominating the book [24], with renewing members now representing 70% of the Marketplace book [25]. Centene, by contrast, is the nation's largest Marketplace insurer and bears the larger absolute share of the same subsidy-expiration shock [8]. Molina's smaller absolute Marketplace book is a competitive advantage in a year when the segment economics are reversing.

5. Where Competitors Beat Molina

Four advantages, named to the specific competitor that holds them.

5.1 UnitedHealth's vertical integration (Optum). UnitedHealth describes itself as two "distinct, yet complementary businesses — Optum and UnitedHealthcare" [13], with Optum Insight providing services, analytics, and platforms back to health plans, employers, and state Medicaid programs [26]. Molina has no equivalent in-house services arm; instead it outsources core IT to a third party under an agreement extended in 2022 for seven additional years [6]. In any state RFP where data-analytics, care-management technology, or health-system services capability is scored, UnitedHealth is structurally better positioned and can cross-subsidize its bid from Optum's profit pool.

5.2 Humana's dominance in individual Medicare Advantage. Humana served approximately 5.2 million individual MA members at year-end 2025 — including roughly 1.0 million in Florida alone [18] — against Molina's total Medicare segment membership of 262,000 [27]. Individual Medicare Advantage alone accounted for 70.3% of Humana's Insurance segment revenue [19]. On any pure MA bid market, Humana brings two orders of magnitude more member-level data, broker relationships, and STARS-rating infrastructure than Molina can. Molina's own 10-K acknowledges Humana as a primary Medicare competitor [7].

5.3 Centene's Marketplace scale and brand. In the Marketplace where Molina is shrinking deliberately, Centene is the largest player and explicitly named as Molina's primary low-income Marketplace competitor [7]. Centene's roughly $36-37 billion Marketplace business (implied at ~21% of $174.6B FY2025 revenue) [8] gives it actuarial credibility, member-acquisition machinery, and broker reach that Molina, with a smaller Marketplace book, cannot match if the segment normalizes after subsidy expiration.

5.4 Elevance and CVS's balance-sheet weight in state-by-state bids. Elevance's 45.2 million medical members and Carelon services arm [15] [28], and CVS's combination of Aetna's 37 million people, Caremark's 87 million PBM relationships, and a national retail-clinic footprint [16], both give them depth on Medicaid RFPs where states score provider network access and integrated services. Aetna's Medicaid/CHIP footprint is already in 15 states [17]. When Molina's 10-K calls out "renewed interest from large national health plans" [6], this is what it means.

6. Threat Map - The Next 24 Months

The five threats below come straight off the primary record, each tied to its cited evidence, severity, and the competitor or competitor group that creates it. Threat 1 is the only one that directly attacks share; the others compress economics inside the existing book.

No Results

Threat 1 - Medicaid bid pressure from large national MCOs (High). Molina's FY2025 10-K explicitly flags this as a current dynamic: "There is increasing competition driven by renewed interest from large national health plans" [6]. It has already cost Molina the Virginia contract — confirmed on the Q4 FY2025 call ("Medicaid is up \$1.1 billion due to the new Florida CMS contract and the modest rate cycle, partially offset by the Virginia contract loss in 2025…") [29]. State agencies score RFPs on provider network, quality scores, financial resources, and other factors [6] — every one of which a $400B+ revenue rival can throw weight at.

Threat 2 - Medicaid trend overrunning state rates (High, near-term). Management quantified the gap: "the industry is 300 to 400 basis points underfunded right now" [2]. The pressure is concrete and showed up in FY2025 results — Medicaid MCR rose 150 basis points to 91.8% driven by higher utilization, behavioral health costs, and member acuity changes [30]. Because rate cycles lag cost cycles by 6-18 months, this threat is largely about when the catch-up arrives, not whether. It is industry-wide, but at Molina's 75% Medicaid revenue concentration, the operating-result sensitivity is higher than at any peer in the table.

Threat 3 - OBBBA Medicaid Expansion membership loss (High, 12-36 months). Management's own quantification: the One Big Beautiful Bill Act "is expected to drive a 15% to 20% reduction on 1.2 million members in our Medicaid Expansion membership and a further medical cost acuity shift during the next two to three years" [20]. This is regulatory, not competitive — but it removes premium revenue from Molina's most concentrated segment and lifts the average acuity of remaining members. Centene's 10-K confirms the same OBBBA mechanism applies across the industry [9], so it is not a competitive share threat — but it shrinks Molina's addressable base.

Threat 4 - Marketplace subsidy expiration and program-integrity rules (Medium). Management explicitly cites "The expiration of subsidies in Marketplace in 2025 will lead to a reduction in membership and result in an adverse acuity shift in the overall market risk pool. Program integrity initiatives will also be a contributing factor to Marketplace membership reduction" [20]. FY2025 Marketplace MCR jumped from 75.4% to 90.6% [31]. Molina is shrinking its book in response [24], but Centene — with the larger Marketplace book — bears the bigger absolute shock.

Threat 5 - Humana scale in individual MA and the D-SNP transition (Medium). Humana's 5.2 million individual MA members and 70% MA revenue concentration give it data, broker reach, and STARS infrastructure Molina cannot match [18] [19]. The threat is amplified by the CMS-mandated transition of MMP plans to integrated D-SNP contracts that took effect January 1, 2026 in Molina's five MMP states — Illinois, Michigan, Ohio, South Carolina, and Texas [32] — a re-bid market where Humana's MA pricing infrastructure may matter more than Molina's Medicaid relationships.

Threat severity at a glance

7. Moat Watchpoints - What to Monitor

Five disclosed signals that will tell an investor whether Molina's position is actually improving or weakening over the next eight quarters. Each is anchored to a number management has already disclosed.

No Results

The numbers in the Baseline column come from: Medicaid MCR 91.8% [30]; industry spread benchmark "200 to 250 basis points better than the industry" [2]; 80% RFP win rate [22]; ~$9B incremental premium in 2025 [20]; G&A ratio 6.6% [4]; Marketplace renewal mix 70% in silver [24] [25]; Medicare segment 262,000 members [27].

What would change the call. If the 200-250bps Medicaid-MCR spread compresses, the operational moat is weakening and the franchise re-rates lower. If RFP win rate slips meaningfully below 80% on rebids in 2026-27, the bid-market share leak from the large national MCOs is real. Conversely, if G&A holds under 7% on a flat or shrinking revenue base, the operating-leverage advantage is structural and not just volume-driven, and the cycle-bottom multiple is wrong.

References

Generated Jun 19, 2026 10:03 UTC